$1.89
Value $151M
NAGE and SHW stock compared: price, dividend, valuation and results, from SEC filings.
$1.89
Value $151M
$340.92
Value $84.5B
Niagen Bioscience (NAGE) has a market value of $151M and Sherwin-Williams (SHW) $84.5B. Over the last year, with dividends, NAGE moved -72.4% and SHW +6.2%. The P/E is 14.8 for NAGE and 31.6 for SHW. Dividend yield: NAGE none, SHW 0.94%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
NAGE$151M
SHW$84.5B
SHW is 558 times NAGE
Revenue, 12 months
NAGE$122M
SHW$24.9B
SHW is 204 times NAGE
Net income, 12 months
NAGE$10M
SHW$2.7B
SHW is 261 times NAGE
Operating margin
NAGE3.9%
SHW–
ROIC
NAGE5.6%
SHW17.7%
12.1 points apart
P/E
NAGE14.8
SHW31.6
SHW is 2.1 times NAGE
Dividend yield
NAGE0.0%
SHW0.9%
0.9 points apart
5-year return
NAGE-65.6%
SHW+7.8%
73.4 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
NAGE-65.6%
SHW+7.8%
| Period | NAGEWith dividends | SHWWith dividends |
|---|---|---|
| 1 year since November 18, 2025 | -72.4%Price -72.4% | +6.2%Price +5.2% |
| 3 years since November 17, 2023 | +32.2%+9.7% a yearPrice +32.2% | +29.4%+9.0% a yearPrice +26.0% |
| 5 years since November 18, 2021 | -65.6%-19.2% a yearPrice -65.6% | +7.8%+1.5% a yearPrice +3.0% |
| 10 years since November 21, 2016 | -24.1%-2.7% a yearPrice -24.1% | +320.3%+15.4% a yearPrice +284.0% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
NAGENiagen BioscienceSHWSherwin-Williams
| Price | $1.89 | $340.92 |
|---|---|---|
| Market value | $151M | $84.5B |
| Enterprise value (EV) | $82M | $94.5B |
| P/E | 14.8 | 31.6 |
| P/E, 5-year median | – | 32.2 |
| P/B | 1.8 | 21.2 |
| EV/EBIT | 17.1 | 27.0 |
| Free cash flow yield | – | 3.6% |
| Revenue, 12 months | $122M | $24.9B |
|---|---|---|
| Net income, 12 months | $10M | $2.7B |
| Free cash flow, 12 months | – | $3.1B |
| Earnings per share, 12 months | $0.12 | $10.88 |
| Revenue growth, year on year | 30.0% | 2.1% |
| Revenue growth a year, past | +16.9%over 5 years | +5.1%over 5 years |
| EPS growth a year, past | – | +6.9%over 5 years |
| Gross margin | 63.9% | 48.6% |
|---|---|---|
| Operating margin | 3.9% | – |
| Net margin | 8.4% | 10.7% |
| ROIC | 5.6% | 17.7% |
| ROE | 13.0% | 62.9% |
| Cash | $70M | $264M |
|---|---|---|
| Total debt | $2.1M | $12.5B |
| Net debt / EBITDA | -12.9 | 2.6 |
| Interest cover | – | 6.5× |
| Dividend yield | – | 0.9% |
|---|---|---|
| Dividend per share, 12 months | – | $3.20 |
| Dividend growth a year, past | – | +12.1%over 5 years |
| Buyback yield | 0.2% | 2.0% |
| Shareholder yield | 0.2% | 2.9% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Sherwin-Williams ($84.5B) is about 558.1 times Niagen Bioscience ($151M), at today's prices.
Since November 21, 2016, NAGE's price moved -24.1% and SHW's +284.0%. With dividends: NAGE -24.1% (-2.7% a year), SHW +320.3% (+15.4% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for Niagen Bioscience and 0.94% for Sherwin-Williams. Over the last twelve months they paid – and $3.20 per share.
At today's price, the P/E is 14.8 for NAGE and 31.6 for SHW. It is the share price over the last twelve months' earnings per share.
Over the last twelve months, the net margin was 8.4% for Niagen Bioscience and 10.7% for Sherwin-Williams, and the operating margin 3.9% and –. Revenue was $122M and $24.9B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.